What this is
- How it works
- How it works isn't classified yet
- Main trialPhase 1
- “This is a Phase 1 dose escalation study using a 3+3 study design, followed by a phase 1b expansion study. The purpose of the TRAVERSE study is to assess the safety, efficacy, and cell kinetics of ALLO-316 in adults with advanced or metastatic clear cell renal cell carcinoma after a lymphodepletion regimen comprising fludarabine, cyclophosphamide, with or without ALLO-647 to define a Phase 2 dose.”In the company’s words, NCT04696731 on ClinicalTrials.gov
Other drugs for Advanced/Metastatic Clear Cell Renal Cell Carcinoma
- CasdatifanArcus Biosciences · Phase 3
- AB-2100Arsenal Biosciences, Inc. · Phase 1/2
- EB-701/CA9-NKBeijing Biotech · Phase 1/2
- AxitinibPfizer · Phase 1/2
- PF-08634404Pfizer · 3SBio · Phase 1/2
- NEO-811Neomorph, Inc · Phase 1
Coming up1
- Jan 2030Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Active, not recruiting | Jan 2030 | Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026